Hostname: page-component-f554764f5-246sw Total loading time: 0 Render date: 2025-04-11T11:50:56.668Z Has data issue: false hasContentIssue false
  • English
  • Français

Neutropenia and Agranulocytosis in Patients Receiving Clozapine in the UK and Ireland

Published online by Cambridge University Press:  02 January 2018

Karen Atkin ,
Francis Kendall ,
Duncan Gould ,
Hugh Freeman ,
Jeffrey Lieberman  and
Desmond O'Sullivan
Karen Atkin*
Affiliation:
Clozaril Patient Monitoring Service, Sandoz Pharmaceuticals
Francis Kendall
Affiliation:
Sandoz Pharmaceuticals
Duncan Gould
Affiliation:
Sandoz Pharmaceuticals
Jeffrey Lieberman
Affiliation:
Albert Einstein College of Medicine, New York
Desmond O'Sullivan
Affiliation:
Sandoz Pharmaceuticals
*
Dr Karen J. Atkin, Senior Medical Adviser in Pharmacovigilance, Clozaril Patient Monitoring Service, Sandoz Pharmaceuticals, Frimley Business Park, Frimley, Surrey GU16 5SG
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Clozapine can cause reversible agranulocytosis and neutropenia. This study documents the occurrence of blood dyscrasias and identifies predisposing risk factors.

Method

An analysis was made of the haematological, demographic, and dosage data from a central database on 6316 patients receiving clozapine over four and a half years in the UK and Ireland.

Results

During the study period 2.9% of the patients developed neutropenia and 0.8% developed agranulocytosis. The peak incidence of both disorders was in the first 6–18 weeks of treatment. Fatal agranulocytosis occurred in 0.03% of patients. After the first year of treatment the incidence of agranulocytosis significantly decreased to the order noted with some phenothiazines.

Conclusions

The use of a patient monitoring service kept the haematological risks associated with using clozapine within acceptable limits, particularly in view of the benefits of this medication in treatment-resistant schizophrenia.

Type
Papers
Information
The British Journal of Psychiatry , Volume 169 , Issue 4 , October 1996 , pp. 483 - 488
Copyright
Copyright © 1996 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Alvir, J. M., Lieberman, J. A., Safferman, A. Z., et al (1993) Clozapine induced agranulocytosis: incidence and risk factors in the United States. New England Journal of Medicine, 329, 162–167.Google Scholar
Böttiger, L. E. & Böttiger, B. (1981) Incidence and cause of aplastic anaemia, hemolytic anaemia agranulocytosis and thrombocytopenia. Acta Medica Scandinavica, 210, 475–479.Google Scholar
Bruhwyler, J., Chleide, E. & Mercier, M. (1990) Clozapine: an atypical neuroleptic. Neuroscience and Biobehavioural Reviews, 14, 357–363.Google Scholar
Kane, J., Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment-resistant schizophrenic: a double blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789–796.Google Scholar
Kane, J., Safferman, A. Z., Pollack, S., et al (1994) Clozapine: negative symptoms and extrapyramidal side effects. Journal of Clinical Psychiatry, 55 (suppl. B), 74–77.Google Scholar
Kaufman, D. W., Kelly, J. P., Levy, M., et al (1991) The Drug Aetiology of Agranulocytosis and Aplastic Anaemia, pp. 148–158. Oxford: Oxford University Press.Google Scholar
Lieberman, J. A., Saltz, B. L., Johns, C. A., et al (1991) The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry, 158, 503–510.CrossRefGoogle ScholarPubMed
Mandel, A. & Gross, M. (1986) Agranulocytosis and phenothiazines. Diseases of the Nervous System, 29, 32–36.Google Scholar
Medicines Control Agency (1993) Drug-induced neutropenia and agranulocytosis. Current Problems in Pharmacovigilance, 20, 10–11.Google Scholar
Meltzer, H. Y. (1992) Dimensions of outcome with clozapine. British Journal of Psychiatry, 160 (suppl. 17), 46–53.Google Scholar
Meltzer, H. Y., Bastani, B., Kwon, K. Y., et al (1989) A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology, 99, S68–S72.Google Scholar
Pisciotta, V. (1978) Drug-induced agranulocytosis. Drugs, 15, 132–143.CrossRefGoogle ScholarPubMed
Reed, W. W. & Diehl, L. F. (1991) Leukopenia, neutropenia, and reduced haemoglobin levels in healthy American blacks. Archives of Internal Medicine, 151, 501–505.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.